Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy
centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and …

Introduction Several patients with myasthenia gravis (MG) do not adequately respond to
available drugs or exhibit poor tolerance, necessitating the need for new therapies. Areas …

Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating rare
disease, often accompanied by high treatment burden and with an unmet need for more …

Background Generalized myasthenia gravis (gMG) is a rare, chronic, and debilitating
autoimmune disease. Activation of the complement system by autoantibodies against the …

Background Myasthenia gravis (MG) leads to exertion-dependent muscle weakness, but
also psychological and social well-being are limited. We aim to describe the burden of …

Background Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG)
are associated with significant lethality and continue to impose a high disease burden on …

Myasthenia gravis (MG) is a chronic autoimmune disease with fluctuating muscle weakness
and fatigability. Standard immunomodulatory treatment may fail to achieve sufficient …

Background and purpose Therapy for myasthenia gravis (MG) is undergoing a profound
change, with new treatments being tested. These include complement inhibitors and …

Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and congenital
myasthenic syndromes (CMS) represent an etiologically heterogeneous group of (very) rare …

There are substantial disease and health-related quality-of-life (HRQoL) burdens for many
patients with myasthenia gravis (MG), especially for those whose disease symptoms are not …